Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 16;12(6):553. doi: 10.3390/metabo12060553

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Protocol of hyperuricemia induction and treatment of rats. Sprague-Dawley rats were intraperitoneal injected with potassium oxonate (PO; 250 mg/kg b.w.) daily to induce hyperuricemia. The rats in the normal (N) group did not receive any treatment throughout the animal experiment. PO-injected rats were randomly divided to 6 groups (n = 8): hyperuricemic control (HC), daily treated with allopurinol (10 mg/kg b.w.; HA), daily treated with GM (200 or 400 mg/kg b.w.; HM2 or HM4), or daily treated with GP (200 or 400 mg/kg b.w.; HP2 or HP4). Except for the rats in N and HC groups, the other rats were orally treated with allopurinol or G. lucidum formula daily. The rats were treated for 2 weeks and then sacrificed on day 15 to individually isolate and weigh the kidney and liver. The blood samples, as well as liver samples, were harvested for further analysis.